fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Stock Market Pulls Back Until Friday’s Solid Rebound – $DIS $F $INMB $INVO $NFLX $TSLA Move Higher

By John F. Heerdink, Jr.
LinkedIn Twitter Disclaimer
Stock Market Pulls Back Until Friday's Solid Rebound
“Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden, American Coach, October 14, 1910 – June 4, 2010


Happy Weekend All!

I hope that you all had a great week and that the overall markets’ weekly pullback did not hit your accounts too significantly. At times this week, it felt like the market would not find a bottom, that is, until Friday’s session brought forth a rebound of sorts.  The US debt ceiling issue was over reported for most of the week as Janet Yellen parroted and preached her worrisome warnings on the subject, which did not set will with investors as it coincided with volatility in the yield curve. Many investors  also locked in their gains for the third quarter which happened to end on Thursday adding to the selloff, a not to uncommon occurrence annually during September. This September was no different as the S&P 500 ended down 4.8%. 

The ongoing supply chain issues also continued to surface this week and remained as a looming cloud, leaving many investors and consumers unsettled. 10 of the 11 sectors closed in the red this week with the energy sector advancing +5.8% as oil prices moved up +2.1% to close at $75.74 up a ridiculous +56.1% YTD.  The influential information technology sector fell a sizable 3.3% & the health care sector faired even worse, dropping 3.5%. But all seemed a bit better on Friday, as the yield curve backed off significantly from its weekly rise/volatility seeing the 10-yr yield settle nearly even wk/wk ending at 1.47% up just 1 basis point, while the 2-yr ended down 1 basis point wk/wk closing at .26%. The U.S. Dollar Index closed at 94.04, up from last Friday’s close of 93.28. 

At the end of the week, the markets closed as follows: The S&P 500 closed at 4,357.04 (-2.2%) & remains up 16% YTD, the Dow 30 closed at 34,326.46 (-1.4%) & remains up 12.2% YTD, & the Nasdaq closed at 14,566.70 (-3.2%) and remains up 13% YTD. The small caps on the Russell 2000 took it significantly on the chin this week and closed at 2,241.63 (-6.4%), but remains up 13.5% YTD. On a slightly bright side, the MicroCaps managed to eke out a win this week as the iShares Micro-Cap ETF (IWC) closed at $146.66, +.38% for the week & is up 23.61% YTD.

MACRO REPORTS

Many more macroeconomic reports surfaced again this week. On Tuesday, the Conference Board’s Consumer Confidence Index report confirmed a fall to 109.3 in September. The Advance report for International Trade in Goods for August confirmed a deficit of $87.6B, while the Advance report for Retail Inventories report for August showed a rise by .1%, & the Advance report for Wholesale Inventories report for August rose 1.2%. The July FHFA Housing Price Index report showed a rise by 1.4% M/M. The July S&P Case-Shiller Home Price Index report confirmed a 19.9% jump Y/Y.
On Wednesday, the Pending home sales report confirmed a 8.1% M/M leap in August, while the weekly MBA Mortgage Applications Index report confirmed a drop by 1.1%. The weekly crude oil inventories rose by 4.58M barrels. On Thursday, the Initial jobless claims report for the week ending September 25, confirmed a rise by by 11k to 362k, while continuing claims for the week ending September 18 fell by 18k to 2.802M. The third estimate for Q2 GDP ticked up to 6.7 & the GDP Deflator remained at 6.1%. The Chicago PMI fell to 64.7 in September. On Friday, the personal income report confirmed a rise by .2% M/M in August, while personal spending rose by .8%. The PCE Price Index report confirmed a rise by .4% M/M, now up 4.3% Y/Y, while the core PCE Price Index moved up by .3% & up 3.6% Y/Y. The personal savings rate decreased to 9.4%. The September ISM Manufacturing Index report came in at 61.1%. The final report for the University of Michigan’s Index of Consumer Sentiment moved higher slightly to 72.8. The total construction spending report stayed pat M/M in August. The final IHS Market Manufacturing PMI report for September moved up to 60.7.

Next week, the macroeconomic schedule will serve the Factory Orders for August, the unemployment rate, and the PMI composite.

STORIES YOU MAY HAVE MISSED

Merck’s Oral COVID-19 Antiviral Drug Showing To Be Efficacious Against Variants

Microsoft Allows Third-Party Storefronts On Its App Store Without Fees

Visa To Expand Operations & Hiring In Midtown Atlanta

Walmart Health Centers Partners With Epic Systems To Offer Easy Access To “e-health” Records

Nike Teams Up With Award-Winning Singer Billie Eilish To Launch “100% Vegan” Air Jordans

FAANG’s – $NFLX FLYS ALONE

The FAANG’s weekly returns were as follows: Apple (AAPL) closed at $142.65, -2.91%, Amazon (AMZN) closed at $3,283.26, -4.15% for the week, Alphabet (GOOG) closed at $2,729.25, -4.33% for the week, Facebook (FB) closed at $343.01, -2.82% this week & Netflix (NFLX) closed at $613.15/share, +3.5%. The MicroSectors FANG+ Index 3X Leveraged ETN (FNGU), which offers 3x leveraged exposure to an index of “FANG” companies, and other companies that exhibit similar characteristics, closed at $33.45, -8.73% for the week. 

Netflix, Inc. (NASDAQ: NFLX) today announced it will post its third-quarter 2021 financial results and business outlook on its investor relations website at http://ir.netflix.net on Tuesday, October 19, 2021, at approximately 1:00 p.m. Pacific Time. At that time, the company will issue a brief advisory release via newswire containing a link to the third-quarter 2021 financial results and letter to shareholders on its website.

EV- TECH 

Leading EV car maker Tesla (TSLA) moved higher to close at $775.22, +.11% for the week. Tesla, Inc. announced updates to its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”). The following updates supersede anything to the contrary described in Tesla’s updated definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 26, 2021. Live video webcasts of the 2021 Annual Meeting event will be accessible to the general public at www.tesla.com/2021shareholdermeeting. 

Shares of Ford Motor Co. (F) moved higher to close at $14.16, +2.76% for the week. On September 22, Ford and Redwood Materials announced they are working together to build out battery recycling and a domestic battery supply chain for electric vehicles. Ford and Redwood’s goal is to make electric vehicles more sustainable, drive down the cost for batteries, and ultimately help make electric vehicles accessible and affordable for more Americans.

Microsoft (MSFT) closed at $289.10, -3.42% for the week. On September 14th, Microsoft Corp. announced that its board of directors declared a quarterly dividend of $0.62 per share, reflecting a 6 cent or 11% increase over the previous quarter’s dividend. The dividend is payable Dec. 9, 2021, to shareholders of record on Nov. 18, 2021. The ex-dividend date will be Nov. 17, 2021. The board of directors also approved a new share repurchase program authorizing up to $60 billion in share repurchases.

Dow 30 component and global leader in CRM, salesforce.com (CRM), closed at $275.26, -3.63% this week.

NVIDIA Corporation closed lower $207.42, -6.06% for the week. 

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $111.17, -5.09% for the week and now about 95 for 2 weeks.

The Technology Select Sector SPDR Fund (XLK) closed at $151.57, -3.28% for the week.


DISNEY

Disney (DIS) closed at $176.01, +.01% for the week.  On Friday, Disney World turned the big “Five-O” and The Walt Disney Company settled their beef with the Black Widow. 

BIOTECH DROPS SIGNIFICANTLY – MRK”S M&A, & CYTOVIA MOVES CLOSER TO IPO!

The Nasdaq Biotechnology ETF (IBB) closed at $158.93, -6.78% for the week, & reminds up 4.91% this year. The NYSE ARCA Biotech Index (^BTK) closed at 5,669.63, -4.05% for the week and is now down -1.21% YTD. In concert this week, the SPDR S&P Biotech ETF (XBI) closed at $126.17, -3.22% for the week and is off 10.38% for the year. The XBI’s 52-wk range is $109.82-$174.79.

M&A continued to surface in the biotech sector this week as Merck (MRK, $81.40, +8.37%) announced that it is acquiring of Acceleron Pharma (XLRN) for ~$11.5B in cash or at $180/share. Acceleron is focused on harnessing the power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Sotatercept is in Phase 3 trials as add-on to current standard of care for the treatment of PAH. Reportedly, the acquisition complements and strengthens Merck’s Cardiovascular Pipeline. XLRN’s Sotatercept is a potentially First-In-Class Therapy in Phase 3 development for the treatment of Pulmonary Arterial Hypertension. XLRN’s REBLOZYL® (luspatercept-aamt) is a First-In-Class Erythroid Maturation Recombinant Fusion Protein approved for the treatment of Anemia in Certain Rare Blood Disorders.

One our portfolio companies in the biotech sector, privately owned Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen Receptor)-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, and CytoLynx Therapeutics (“CytoLynx), its newly-formed China-focused joint venture, announced recently that they have closed $45 million from institutional investors to finance the IND enabling and initial clinical development of their pipeline. Cytovia’s management is currently targeting to go public in early-mid 2022.  Note that, Cytovia and TF Capital, a leading China-based biotech institutional investor, have formed CytoLynx Therapeutics. TF Capital along with YF Capital, BioTrack Capital, Ruihua Capital, and TG Sino-Dragon Fund (backed by TigerMed) have invested $45 million to support the new venture, as well as Cytovia research and development projects. The collaboration agreements between CytoLynx and Cytovia will advance multiple NK therapeutics through product development in the Greater China region. Additionally, CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization. Cytovia is eligible to receive up to $400 million in upfront development and commercial milestones under the agreement. The bankers from the largest IBanks are now circling their wagons and the valuation estimates are swelling as they consider swiftly moving forward with a Series C round with the who’s who in the world of institutional biotech investors and then pushing towards and IPO!

I hosted a FREE Tribe Public Presentation and Q&A event with INMB management today, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.

GOLD & SILVER

Gold prices close at $1,762 up $10 for the week & silver prices closed lower at $22.57. +$.14/oz for the week.

MEMES REPORT

AMC Entertainment (AMC), closed at $38.46, -3.87% for the week & GameStop (GME) closed at $176.91, -4.46% for the week. 

Virgin Galactic Holdings (SPCE) closed at $23.83, -4.83% for the week. On Wednesday SPCE, a vertically integrated aerospace and space travel company, announced that it is cleared to fly FAA-licensed spaceflights following the conclusion of an FAA inquiry that focused on air traffic control clearance and real-time mission notification related to the Unity 22 flight in July. Michael Colglazier, Chief Executive Officer of Virgin Galactic, said: “Our entire approach to spaceflight is guided by a fundamental commitment to safety at every level, including our spaceflight system and our test flight program. We appreciate the FAA’s thorough review of this inquiry. Our test flight program is specifically designed to continually improve our processes and procedures. The updates to our airspace and real-time mission notification protocols will strengthen our preparations as we move closer to the commercial launch of our spaceflight experience.”

Infamous ‘meme brokerage’ firm Robinhood Markets, Inc., (HOOD) moved higher this week closing at $41.90, -6.7% for the week & still higher then IPO shares which were sold at $38 this year! 

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $1.43, +.7% for the week. SHIP is the ‘only pure-play Capesize ship-owner publicly listed in the US’, recently announced that its Board of Directors has authorized a share repurchase plan. Under the Plan, the Company may repurchase up to $17 million of its outstanding common shares, representing approximately 10% of the Company’s market capitalization as of August 10, 2021.

Bitcoin

Bitcoin $BTC.X closed at $48,141.46, +9.97% for the week. 

NEXT WEEK

The markets will enjoy another normal 5-day trading week.

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


  • Shares of INmune Bio, Inc. (NASDAQ: INMB) moved higher closing at $20.38, up +1.19% this week. The 52-wk range is $7.28 – $29.99.
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management today, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.
    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
    • On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
    • On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded” said RJ Tesi MD, CEO of Inmune Bio.
    • On July 12th,  INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.
    • On July 7th, The Maxim Group’s analyst raised his price target from $32 to $42 today.

    • On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.



  • InMed Pharmaceuticals, Inc. (NASDAQ: INM) is leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids. Please visit the INM page at our website to learn more and check out the videos section too.  
  • Shares of InMed closed trading this week at $1.70, -6.59% for the week. The 52-wk range is $2.05 -$8.94. 
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
    • I hosted INM’s management team on the Tribe Public Network on Tuesday, September 21 for a 30-minute FREE Presentation and Q&A Webinar Event. Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) & Shane Johnson, MD, Co-Founder of BayMedica delievered a presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” They held a Q&A session at the end of the presentation. You may view the video of the event at the Tribe Public YouTube Channel here.
    • On Friday morning, September 24,  InMed reported their full year Fiscal 2021 financial results and provided a business update. The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2021, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov. Eric A. Adams, InMed CEO, stated, “In the final quarter of our of fiscal year 2021, as well as throughout the year, we made important progress in corporate development, pharmaceutical drug development and in advancing our proprietary manufacturing approach, IntegraSyn™. With the recent announcements regarding our acquisition of BayMedica Inc., the Company is well positioned to continue its activities to solidify a leadership position in the field of rare cannabinoids.”
    • On September 13th, InMed announced that it has entered into a definitive agreement  to acquire BayMedica Inc., a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector. Revenues of BayMedica’s initial rare cannabinoid product, Prodiol® CBC (cannabichromene), have grown steadily since sales commenced in December 2019, with cumulative revenues in excess of US$2.5M. BayMedica leads the industry in large batch production of CBC with current batch sizes of more than 200kg and an ability to increase to metric ton quantities as market demand increases. BayMedica is focused on the wholesale to consumer health and wellness markets, including nutraceuticals, cosmetic, functional food and beverage, as well as animal health markets. In addition to CBC, BayMedica has several high value non-intoxicating rare cannabinoids in various stages of commercial manufacturing scale-up including CBDV, THCV, CBGV, CBT and CBN for the health and wellness markets.
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.

    • On July 2, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.

    • On Thursday, June 17th, InMed Pharmaceuticals (NASDAQ: INM) announced that its continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. InMed’s cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields. The Company has continued to make important steps to further optimize the IntegraSyn™ manufacturing process, resulting in the improved yield of 5 g/L, surpassing InMed’s previously reported yield levels of 2 g/L, an already commercially viable yield. The impact of improved yield is a significant reduction in the overall cost of manufacturing due to greater amount of cannabinoid produced per batch. InMed is now focused on manufacturing scale-up to larger batch sizes in the second half of calendar year 2021. “We are very excited by these impressive yield levels that further validates the IntegraSyn™ manufacturing approach as a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids. While we continue to refine the process, we are now focused on advancing the program towards the next key milestones, including the manufacture of our first large-scale batch through a GMP-ready process in the coming months. We continue to believe InMed’s proprietary IntegraSyn™ approach will be one of the most important manufacturing processes for pharma-grade cannabinoids,” stated Eric A. Adams, President and Chief Executive Officer of InMed.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $59.50, -8.25% for the week. The 52-wk high is $121.16.
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $3.25, -3.85% for the week. 
    • On September 30, September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On September 7th, Atossa adjourned its special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date. The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote. Atossa stockholders may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  •  

  • Shares of  INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.38, +2.92% for the week.  
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions. The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”

    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”

INVO

    • On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.
    • On June 15th, INVO Bioscience, Inc. (NASDAQ: INVO), announced further foundational progress as they appointed of Andrea Goren as the Company’s Chief Financial Officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.
    • On May 17, INVO announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update. Steve Shum, Chief Executive Officer of INVO Bioscience stated, “This was an exciting start to the year 2021 for INVO Bioscience as we advanced our INVO Clinic strategy with the signing of our first U.S.-based INVOcell exclusive facility in Birmingham, Alabama, the signing of a partnership agreement to establish and operate a center in Northern California, and the completion of our product registration in Mexico. We expect these initial centers to become operational in the second half of the year. Throughout this year, we have expanded our real-world experience data and positive results with INVOcell, enhanced our online training tools, materials, and capabilities and have experienced a substantial increase in active training sessions for our international partners and distributors. We believe the combination of strong commercialization partnerships and company-owned clinics, both in the U.S. and around the world, is key to expanding INVOcell’s adoption within the fertility industry. In addition to the progress made executing new commercialization agreements, we have strengthened our marketing capabilities to support the INVOcell-only centers and our growing number of distribution partners. Meryle Lynn Chamberlain, a tenured women’s health and fertility solution marketing professional, joined us as Director of Marketing in March 2021, while Rebecca Messina, current Senior Advisor at McKinsey & Co. and former Global Chief Marketing Officer at both Uber and Beam Suntory joined our board of directors in April 2021. As we look to increase access to care and expand fertility treatment across the globe, our market positioning and overall strategies are more important than ever. The addition of Meryle Lynn and Rebecca will enhance our ability to successfully accomplish these goals. As we look to the remainder of 2021, we have set a number of key objectives, including the opening of our first company-owned clinics in Mexico and the United States. Additionally, we will seek to build our international revenues this year through our growing list of international distribution partners as they finish training, and we complete local product registration requirements. Of note, we are extremely pleased to see the initial INVO procedures performed recently in Spain and Malaysia, which reflects the groundwork done by our team in these specific markets, which we believe will help in further expanding the overall awareness of the potential outside of the U.S. Finally, we are continuing to advance our 5-day label expansion efforts with the FDA in the U.S. market with a goal of completing this effort in 2021. It remains our belief that there is strong global demand for fertility services and INVOcell is well-positioned through our growing, global footprint to play a key role in helping to turn the dream of creating a family for millions of people around the world into a reality through our accessible, efficient, and affordable fertility treatment.”
    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Investing & Inspiration

  1. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  2. “One fails forward toward success.” – Charles Kettering
  3. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  4. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  5. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  6. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  7. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  8. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  9. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  10. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  11. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  12. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  13. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  14. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  15. “It takes a long time to grow an old friend.” – John Leonard
  16. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  17. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  18. “Man is only great when he acts from passion.” – Benjamin Disraeli
  19. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  20. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  21. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  22. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  23. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  24. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  25. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  26. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  27. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  28. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  29. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  30. “Every good painter paints what he is.” – Jackson Pollock
  31. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  32. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  33. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  34. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  35. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  36. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  37. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  38. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  39. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 

  40. “Eliminate emotion from your investment program.” -John C. Bogle

  41. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  42. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  43. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  44. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  45. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  46. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  47. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  48. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  49. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  50. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  51.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  52. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  53. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey

  54. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  55. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  56. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

  57. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  58. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  59. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  60. “Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)

  61. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  62. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  63. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  64. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  65. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  66. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem

  67. “View health as an investment, not an expense.” – John Quelch

  68. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  69. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  70. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  71. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  72. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  73. “A problem is a chance for you to do your best.”–  Duke Ellington
  74. “The best way to predict the future is to create it.” -Peter Drucker
  75. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  76. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  77. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  78. “While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  79. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  80. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  81. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  82. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant

  83. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  84. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill

  85. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  86. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  87. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  88. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  89. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  90. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  91. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger

  92. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  93. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  94. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu

  95. “Modern medical advances have helped millions of people live longer, healthier lives.

  96. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  97. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  98. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  99. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  100. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  101. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  102. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  103. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  104. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  105. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  106. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  107. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  108. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.

  109. “Investment is most successful when it is most businesslike.” – Ben Graham

  110. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  111. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  112. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  113. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  114. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  115. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  116. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  117. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  118. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  119. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  120. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  121. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  122. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  123. “Know what you own, and know why you own it.” – Peter Lynch
  124. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  125. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz

  126. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  127. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  128. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  129. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett

  130. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  131. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  132. “Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  133. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  134. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  135. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  136. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  137. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  138. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  139. “The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  140. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  141. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  142. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  143. “No Price is too low for a bear or too high for a bull.” — Anonymous
  144. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  145. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  146. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  147. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  148. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  149. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  150. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  151. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  152. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  153. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  154. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  155. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  156. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  157. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  158. “Know what you own, and know why you own it.” – Peter Lynch
  159. “Liquidity is only there when you don’t need it.” -Old Proverb
  160. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  161. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  162. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  163. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  164. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  165. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  166. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  167. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  168. “I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  169. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  170. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  171. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  172. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  173. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  174. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  175. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  176. “Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  177. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  178. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  179. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  180. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  181. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos:

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

We value your privacy and will never share your information.

Recent Posts

VP Watchlist

Trending Posts